Using small antibodies to diagnose and treat Alzheimer's disease
Single domain antibodies for diagnosis and treatment of synucleinopathies
This study is exploring new, smaller antibodies that could help find and remove harmful proteins linked to Alzheimer's disease, aiming to create better ways to diagnose and treat patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10915130 on NIH RePORTER |
What this research studies
This research focuses on developing single domain antibodies that can target and potentially clear harmful proteins associated with Alzheimer's disease, such as amyloid-β and α-synuclein. By utilizing smaller antibody fragments, the study aims to improve diagnostic imaging and therapeutic efficacy compared to traditional whole antibodies. The researchers will assess the ability of these antibodies to detect and eliminate these proteins in living organisms, which could lead to innovative treatment options for patients. The project involves advanced techniques such as phage display libraries and in vivo imaging to evaluate the effectiveness of these antibody fragments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related synucleinopathies.
Not a fit: Patients with other forms of dementia not related to amyloid-β or α-synuclein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective diagnostic tools and treatments for Alzheimer's disease, improving patient outcomes.
How similar studies have performed: While immunotherapies targeting amyloid-β and α-synuclein are being explored, the specific use of single domain antibodies is a novel approach that has not been extensively tested.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Sigurdsson, Einar M — New York University School of Medicine
- Study coordinator: Sigurdsson, Einar M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.